THE MEDICINES PATENT POOL
EXPANDING ACCESS TO PUBLIC HEALTH
IMPLEMENTATION OF DACLATASVIR LICENCE

Development Report
2017-March 2021
BMS-MPP DACLATASVIR LICENCE: CURRENT SUBLICENSEES

7 daclatasvir sublicensee agreements

Data as of March 2021
MPP LICENSEES HAVE DEVELOPED DAC 30/60 MG AND ARE READY TO COMMERCIALIZE THE PRODUCT

Licensees Approved: Cipla, Hetero, Laurus, Mylan (60mg)

Note: Each triangle represents a manufacturer and timelines represent date of filing
Generic DAC has been filed in 52 countries, of which approval has been received in 34 countries. Filings have occurred where 74% PLHCV^ reside in the licensed territory#.

### APPROVED (34) 67% PLHCV

<table>
<thead>
<tr>
<th>Country</th>
<th>Country</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benin</td>
<td>Guyana</td>
<td>Pakistan</td>
</tr>
<tr>
<td>Burkina Faso</td>
<td>India</td>
<td>Philippines</td>
</tr>
<tr>
<td>Cambodia</td>
<td>Indonesia</td>
<td>Tanzania</td>
</tr>
<tr>
<td>Cameroon</td>
<td>Kazakhstan</td>
<td>Turkmenistan</td>
</tr>
<tr>
<td>Chad</td>
<td>Kyrgyzstan</td>
<td>Uganda</td>
</tr>
<tr>
<td>Congo, Dem. Rep.</td>
<td>Liberia</td>
<td>Ukraine</td>
</tr>
<tr>
<td>Congo, Rep.</td>
<td>Malawi</td>
<td>Uzbekistan</td>
</tr>
<tr>
<td>Côte d'Ivoire</td>
<td>Malaysia</td>
<td>Vietnam</td>
</tr>
<tr>
<td>Dominican Republic</td>
<td>Myanmar</td>
<td>Zambia</td>
</tr>
<tr>
<td>Ethiopia</td>
<td>Myanmar</td>
<td>Zimbabwe</td>
</tr>
<tr>
<td>Gabon</td>
<td>Nicaragua</td>
<td></td>
</tr>
<tr>
<td>Ghana</td>
<td>Nigeria</td>
<td></td>
</tr>
</tbody>
</table>

### FILED (18) 7% PLHCV

<table>
<thead>
<tr>
<th>Country</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azerbaijan</td>
<td>Mozambique</td>
</tr>
<tr>
<td>Bolivia</td>
<td>Namibia</td>
</tr>
<tr>
<td>Botswana</td>
<td>Nepal</td>
</tr>
<tr>
<td>Burundi</td>
<td>Paraguay</td>
</tr>
<tr>
<td>Georgia</td>
<td>Rwanda</td>
</tr>
<tr>
<td>Guatemala</td>
<td>Senegal</td>
</tr>
<tr>
<td>Haiti</td>
<td>Suriname</td>
</tr>
<tr>
<td>Honduras</td>
<td>Thailand</td>
</tr>
<tr>
<td>Kenya</td>
<td>Togo</td>
</tr>
</tbody>
</table>

- Vis-à-vis last update (Q4-20)
- Countries where either DAC 30mg or DAC 60mg have been sold indicated in **bold type**
- ^ People living with Hepatitis C
- **Note:** Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions
- # MPP-BMS DAC licence agreement

Data as of March 2021
DAC 30mg or 60mg sales have occurred in 34 countries where MPP licensees have supplied more than 1.2 Million treatments*, in which 67.8% of PLHCV^ reside in the licensed territory#.

Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions.

^ People living with Hepatitis C
# MPP-BMS DAC licence agreement

*Note: 1 HCV treatment = 12 weeks therapy (3 packs)
3.6 million packs of DAC 30/60mg sold till March 2021

DAC 30/60mg Sales over the years by MPP Partners

*Note: 1 HCV treatment = 12 weeks therapy (3 packs)
DAC has been supplied in **34** countries as of March 2021 by MPP partners. While India constitutes 75% of the volume, 25% can be attributed to the countries shown here.

*Non-identified countries are a result of sales made through procurement agencies

**Others include countries in which fewer than 10,000 packs were sold
1 MPP LICENSEE (MYLAN) HAS DEVELOPED DAC/SOF AND IS READY TO SUPPLY
Generic DAC/SOF has been filed in 18 countries, of which approval has been received in 11 countries.

Filings have occurred where 34.9% of PLHCV\(^{^\text{\footnotesize^}}\) reside in the licensed territory\(^{#}\)

### APPROVED (11)
29.7% PLHCV

- Côte d'Ivoire
- Ethiopia
- Ghana
- India
- Malawi
- Myanmar
- Nicaragua
- Nigeria
- Uganda
- Zambia
- Zimbabwe

### FILED (7)
5.2% PLHCV

- Guyana
- Kenya
- Namibia
- Paraguay
- Suriname
- Tanzania
- Vietnam

- New filings and approvals in green vis-à-vis last update (Q4-20)
- Countries where DAC/SOF has been sold indicated in \textbf{bold type}
- \(^{^\text{\footnotesize^}}\) People living with Hepatitis

\textbf{Note:} Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

\(^{#}\) \textbf{MPP-BMS DAC licence agreement}

\textbf{Data as of March 2021}
MPP licensees have supplied more than **100,000** packs* of generic DAC/SOF across: Cambodia, Ethiopia, India, Laos, Myanmar, Nigeria, South Africa, Uganda, Vietnam

*Packs of 28*
THANK YOU